KHDRBS1 and plasma cell myeloma: Small molecules targeting Sam68, such as CWP232291 [48], has been already considered for phase I clinical studies in myeloma (NCT02426723) and in acute myeloid leukemia and myelodysplastic syndrome (NCT01398462) patients, posing this molecule as a safe and efficacious compound to sensitize relapsed and refractory neoplasia to standard therapies [49].